Familial Pancreatic Cancer PROPHilation Program in Italy
Recruiting · NCT05724992 · Interventional (participants receive a specific treatment) · Lead sponsor: Associazione Italiana per lo Studio del Pancreas
View the official record on ClinicalTrials.gov →Interventions studied
Saliva swab testing
What this trial is about
The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only. Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test. Up to 3,000 participants will be enrolled in this study.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Being enrolled on the IRFARPC registry
- Having familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020)
- Willingness to participate in saliva-swab-based genetic testing
Exclusion criteria
- \- Already known genetic mutation
Where it is running
1 location listed.
- Chirurgia generale e del Pancreas Azienda Ospedaliera Universitaria Integrata - Verona, Italy